main content start
Rybelsus (semaglutide) is a once-daily tablet in the GLP-1 receptor agonist class of drugs. It is used in adults with type 2 diabetes.
Rybelsus helps to release insulin and lowers the amount of glucose produced by the liver when blood glucose rises at mealtime. It also slows the absorption of mealtime glucose.
Rybelsus has been shown to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events.
- Rybelsus is used to help adults with type 2 diabetes to reduce A1C levels by managing their blood glucose. It is not for treating type 1 diabetes.
- Rybelsus has been shown to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk.
- Rybelsus tablets are to be taken once a day when you first wake up and at least 30 minutes before eating or drinking.
- An initial dose of Rybelsus is usually 3 mg once a day for 30 days, then increased to 7 mg. A maintenance dose is 7–14 mg.
- Common side effects may include low blood glucose (in people with type 2 diabetes), upset stomach, heartburn, burping, gas, bloating, nausea, vomiting, stomach pain, loss of appetite, diarrhea, constipation, runny nose or sore throat, stomach flu symptoms, headache, dizziness, or tiredness.
Rybelsus Specs
Key specification
Generic Name
Semaglutide
Drug Class
GLP-1 receptor agonists
General Information
Product Name
Rybelsus
Product Type
Oral Medications
Brand
Novo Nordisk
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
